<DOC>
	<DOCNO>NCT02933775</DOCNO>
	<brief_summary>This study design determine safety relative engraftment level redirect autologous T cell transduce anti-CD19 lentiviral vector patient CD19-positive B cell leukemia malignant lymphoma .</brief_summary>
	<brief_title>CD19-redirected Autologous Cells ( CAR-CD19 T Cells )</brief_title>
	<detailed_description>A single arm open-label pilot study design determine safety , tolerability engraftment potential CAR-CD19 T cell patient CD19-positive malignant B cell leukemia lymphoma . All subject receive CAR-CD19 T cell infusion . Primary objective : 1 . Determine safety feasibility chimeric antigen receptor T cell transduce anti-CD19 lentiviral vector ( refer `` CAR-CD19 T '' cell ) . 2 . Determine duration vivo survival CAR-CD19 T cell . Secondary objective : 1 . For patient detectable disease , measure anti-tumor response due CAR-CD19 T cell infusion . 2 . To determine amplification survival CAR-CD19 T 4-1BB : CD3ζ CD28 : CD3ζ measure relative engraftment level CAR-CD19 T 4-1BB : CD3ζ CD28 : CD3ζ cell time . 3 . Estimate relative traffic CAR-CD19 T cell tumor bone marrow lymphnodes . 4 . Determine cellular humoral host immunity develop murine anti-CD19 , assess correlation loss detectable CAR-CD19 T ( loss engraftment ) . 5 . Determine relative subset CAR-CD19 T cell .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , B-Cell</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<criteria>Subjects document CD19positive malignant B cell leukemia lymphoma . 1 . Patients age 18 ~ 65 malignant B cell leukemia lymphoma . 2 . CD19positive B cell leukemia lymphoma . 3 . Expected survival &gt; 12 week . 4 . ECOG score 01 , KPS score &gt; 80 . 5 . Adequate venous access apheresis venous sampling , contraindication leukapheresis . 6 . WBC ≥ 2.5×109/L ; LY ≥ 0.7×109/L ; LY % ≥ 15 % . 7 . Creatinine ≤ 2.0 mg/dL ( 176.8 μmol/L ) . 8 . ALT/AST ≤ 2.5 ULN . 9 . Bilirubin ≤ 2.0 mg/dL ( 34.2 μmol/L ) . 10 . Prothrombin Time ( PT ) : International Normalized Ratio ( INR ) &lt; 1.7 , PT 4 long normal value . All test result comply criterion . No continue supportive care receive . 1 . CD19negative B cell leukemia lymphoma . 2 . Feasibility assessment screen demonstrate &lt; 5 % transduction target lymphocytes , insufficient expansion ( &lt; 5fold ) response αCD3/CD28 costimulation . 3 . Pregnant lactating woman . ( The safety therapy unborn child know . Female study participant reproductive potential must negative serum urine pregnancy test perform within 48 hour infusion . ) 4 . Active hepatitis B hepatitis C infection . 5 . HIV/AIDS infection . 6 . Uncontrolled active infection . 7 . Concurrent use systemic steroid . Recent current use inhale steroid exclusionary . 8 . Previously treatment gene therapy product . 9 . Allergy immunotherapy associate drug . 10 . Patients heart disease need treatment poorly control hypertension determine investigator . 11 . Patients unstable active ulceration gastrointestinal bleeding . 12 . Patients previous plan organ transplantation . 13 . Hyponatremia concentration sodium blood &lt; 125 mmol/L . 14 . Serum potassium ( baseline ) &lt; 3.5 mmol/L ( Patients take potassium supplement recover serum potassium level prior participate study ) . 15 . Patients need anticoagulant ( e.g . Warfarin heparin ) . 16 . Patients need longterm antiplatelet agent ( Aspirin , dose &gt; 300 mg/d ; Clopidogrel , dose &gt; 75 mg/d ) . 17 . Any radiotherapy conduct within 4 week prior blood sampling .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>